Allarity Therapeutics (NASDAQ:ALLR – Get Free Report) and Tevogen Bio (NASDAQ:TVGN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, analyst recommendations and earnings.
Earnings & Valuation
This table compares Allarity Therapeutics and Tevogen Bio”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Allarity Therapeutics | N/A | N/A | -$24.51 million | ($8.11) | -0.18 |
| Tevogen Bio | N/A | N/A | -$13.73 million | ($0.19) | -3.31 |
Profitability
This table compares Allarity Therapeutics and Tevogen Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Allarity Therapeutics | N/A | -173.31% | -102.57% |
| Tevogen Bio | N/A | N/A | -775.49% |
Insider & Institutional Ownership
11.5% of Allarity Therapeutics shares are owned by institutional investors. 0.0% of Allarity Therapeutics shares are owned by company insiders. Comparatively, 73.2% of Tevogen Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
Allarity Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of -0.86, indicating that its stock price is 186% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings and price targets for Allarity Therapeutics and Tevogen Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Allarity Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
| Tevogen Bio | 1 | 0 | 1 | 0 | 2.00 |
Allarity Therapeutics presently has a consensus target price of $9.25, suggesting a potential upside of 537.93%. Tevogen Bio has a consensus target price of $10.00, suggesting a potential upside of 1,491.34%. Given Tevogen Bio’s higher possible upside, analysts clearly believe Tevogen Bio is more favorable than Allarity Therapeutics.
Summary
Tevogen Bio beats Allarity Therapeutics on 5 of the 9 factors compared between the two stocks.
About Allarity Therapeutics
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.
About Tevogen Bio
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
